| |
|
| |
Function |
Assistant professor of Biochemistry
|
 |
|
| Research area |
Theme I |
| Phone / fax |
|
| Email |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
|
| |
|
|
| |
| Dr. Reutelingsperger studied biochemistry at the University of Utrecht where he graduated in 1981. In the same year he started to work as a PhD.-student at Universiteit Maastricht. He discovered a new protein Vascular Anticoagulant, now termed Annexin V, and recognized its potency as an antithrombotic agent for the treatment of haemostatic disorders. He generated 5 world wide patents protecting this invention. In 1987 he defended his thesis "Vascular Anticoagulant: A new physiological anticoagulant mechanism". In the same year he was appointed as a senior research fellow of the Royal Dutch Academy of Sciences. In this position he continued his research on Annexin V at Universiteit Maastricht and at the Boehringer Instituut fuer Arzneimittelforschung in Vienna. In 1992 he joined the staff of the department of Biochemistry at Universiteit Maastricht and continued his fundamental and clinically applied research on Annexin V. In 1993 he discovered the concept to measure apoptosis by Annexin V in vitro and in vivo. He protected this application by a world wide patent. In 1997 he co-developed the first clinical studies in which the concept of Annexin V is used as a radiodiagnostic probe to visualize and localize apoptosis in patients in order to guide diagnosis and therapy decision making. Hence, he covered successfully the whole process from discovery on the laboratory bench until the use in the clinic for a concept and a product. Currently, he is principle investigator of CARIM. |
|
|
|
top
